Bone marrow conditioning regimen and Urinary tract infection

Summary:

Urinary tract infection is found among people with Bone marrow conditioning regimen, especially for people who are male, 50-59 old.

The study analyzes which people have Urinary tract infection with Bone marrow conditioning regimen. It is created by eHealthMe based on reports of 95 people who have Bone marrow conditioning regimen from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Bone marrow conditioning regimen?

Bone marrow conditioning regimen is found to be associated with 1 drug and 2 conditions by eHealthMe. Check the latest studies of Bone marrow conditioning regimen.

What is Urinary tract infection?

Urinary tract infection is found to be associated with 3,014 drugs and 3,956 conditions by eHealthMe. Check the latest studies of Urinary tract infection.

On Jul, 17, 2026

95 people who have Bone Marrow Conditioning Regimen and Urinary Tract Infection are studied.

Would you have Urinary tract infection when you have Bone marrow conditioning regimen?

Gender of people who have Bone Marrow Conditioning Regimen and experienced Urinary Tract Infection *:

female: 40.96 %
male: 59.04 %

Age of people who have Bone Marrow Conditioning Regimen and experienced Urinary Tract Infection *:

Common co-existing conditions for these people *:

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 8 people, 8.42%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 6 people, 6.32%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 6 people, 6.32%
Fever: 5 people, 5.26%
Insomnia (sleeplessness): 4 people, 4.21%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 4 people, 4.21%
Acute Graft Versus Host Disease In Skin (acute complication on skin following an allogeneic tissue/blood transplant): 3 people, 3.16%
Depression: 3 people, 3.16%
Pulmonary Embolism (blockage of the main artery of the lung): 3 people, 3.16%
High Blood Pressure: 3 people, 3.16%

Common drugs taken by these people *:

Cyclophosphamide: 21 people, 22.11%
Cyclosporine: 20 people, 21.05%
Mycophenolate Mofetil: 19 people, 20.00%
Tacrolimus: 18 people, 18.95%
Methylprednisolone: 14 people, 14.74%
Methotrexate: 14 people, 14.74%
Melphalan: 14 people, 14.74%
Busulfan: 14 people, 14.74%
Ciclosporin: 13 people, 13.68%
Ondansetron: 8 people, 8.42%

Common symptoms for these people *:

Bk Virus Infection: 28 people, 29.47%
Fever: 17 people, 17.89%
Acute Graft Versus Host Disease In Skin (acute complication on skin following an allogeneic tissue/blood transplant): 14 people, 14.74%
Sepsis (a severe blood infection that can lead to organ failure and death): 12 people, 12.63%
Cytomegalovirus Infection: 11 people, 11.58%
Mucosal Inflammation (infection of mucous membrane): 11 people, 11.58%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 9 people, 9.47%
Acute Graft Versus Host Disease In Intestine (acute complication in intestine following an allogeneic tissue/blood transplant): 9 people, 9.47%
Pneumonia: 9 people, 9.47%
Febrile Neutropenia (fever with reduced white blood cells): 9 people, 9.47%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Urinary tract infection?

- Check whether Urinary tract infection is associated with a drug or a condition

Related studies:

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Urinary tract infection and Bone marrow conditioning regimen, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.